187 related articles for article (PubMed ID: 22072418)
1. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
Bodurka DC; Deavers MT; Tian C; Sun CC; Malpica A; Coleman RL; Lu KH; Sood AK; Birrer MJ; Ozols R; Baergen R; Emerson RE; Steinhoff M; Behmaram B; Rasty G; Gershenson DM
Cancer; 2012 Jun; 118(12):3087-94. PubMed ID: 22072418
[TBL] [Abstract][Full Text] [Related]
2. Grading ovarian serous carcinoma using a two-tier system.
Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG
Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
[TBL] [Abstract][Full Text] [Related]
3. Validation of a two-tier grading system in an unselected, consecutive cohort of serous ovarian cancer patients.
Battista MJ; Cotarelo C; Almstedt K; Heimes AS; Makris GM; Weyer V; Schmidt M
Arch Gynecol Obstet; 2016 Sep; 294(3):599-606. PubMed ID: 26993518
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
5. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
[TBL] [Abstract][Full Text] [Related]
6. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma.
Malpica A; Deavers MT; Tornos C; Kurman RJ; Soslow R; Seidman JD; Munsell MF; Gaertner E; Frishberg D; Silva EG
Am J Surg Pathol; 2007 Aug; 31(8):1168-74. PubMed ID: 17667538
[TBL] [Abstract][Full Text] [Related]
7. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
8. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
9. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
[TBL] [Abstract][Full Text] [Related]
10. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
11. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
[TBL] [Abstract][Full Text] [Related]
12. Is the two-tier ovarian serous carcinoma grading system potentially useful in stratifying uterine serous carcinoma? A large multi-institutional analysis.
Ahmed Q; Hussein Y; Hayek K; Bandyopadhyay S; Semaan A; Abdul-Karim F; Al-Wahab Z; Munkarah AR; Elshaikh MA; Alosh B; Nucci MR; Van de Vijver KK; Morris RT; Oliva E; Ali-Fehmi R
Gynecol Oncol; 2014 Feb; 132(2):372-6. PubMed ID: 24262874
[TBL] [Abstract][Full Text] [Related]
13. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum.
Seidman JD; Horkayne-Szakaly I; Cosin JA; Ryu HS; Haiba M; Boice CR; Yemelyanova AV
Gynecol Oncol; 2006 Nov; 103(2):703-8. PubMed ID: 16828848
[TBL] [Abstract][Full Text] [Related]
14. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
17. Survival in women with grade 1 serous ovarian carcinoma.
Nickles Fader A; Java J; Ueda S; Bristow RE; Armstrong DK; Bookman MA; Gershenson DM;
Obstet Gynecol; 2013 Aug; 122(2 Pt 1):225-232. PubMed ID: 23969788
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
19. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
20. Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).
Vatansever D; Taskiran C; Mutlu Meydanli M; Gungorduk K; Akbayir O; Yalcin I; Demirkiran F; Sozen H; Ozgul N; Celik H; Onan MA; Taskin S; Oge T; Simsek T; Abboud S; Yuksel IT; Ayhan A
J Surg Oncol; 2021 May; 123(8):1801-1810. PubMed ID: 33657253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
